RBC Capital analyst Kennen MacKay maintained a Hold rating on Acceleron Pharma (NASDAQ:XLRN) on Tuesday, setting a price target of $72, which is approximately 31.49% below the present share price of $105.1.
MacKay expects Acceleron Pharma to post earnings per share (EPS) of -$0.44 for the second quarter of 2020.
The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in Acceleron Pharma, with an average price target of $112.5.
The analysts price targets range from a high of $137 to a low of $72.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $39.34 million and a net profit of -$25.58 million. The company's market cap is $5.39 billion.
According to TipRanks.com, RBC Capital analyst Kennen MacKay is a 5-star analyst with an average return of 11.9% and a 56.9% success rate.
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.